TCRT earnings date and last-quarter result: next report 2026-08-18, last quarter beat, P/E -0.90. Updated 2026-07-23.
Alaunos Therapeutics (TCRT) Research Hub
Alaunos Therapeutics (TCRT) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-10-26, shares last closed at 2.13 USD (-6.58%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.90, market cap 0.00B. This hub links to the full technical, earnings and options research available for TCRT.
Last updated 2026-10-26 · Source: end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.13 USD (-6.58%) |
| 52-week range | 0.719 USD – 4.37 USD |
| Trend regime | Range |
| 14-day RSI | 62.3 (Bullish) |
| Trailing P/E | -0.90 |
| Market cap | 0.00B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-18 |
Available research for TCRT
Covered Call on TCRT: how it works, illustrative setup around the real 2.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on TCRT: how it works, illustrative setup around the real 2.13 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on TCRT: how it works, illustrative setup around the real 2.13 USD price, max profit/loss, breakeven and when to use it. Educational.
TCRT technical analysis: range, last 2.13 USD, RSI 62.3, 52w range 0.719 USD–4.37 USD, real support/resistance. Updated 2026-10-26.
More on SniperIQ
Frequently asked questions
What sector is TCRT in?
Alaunos Therapeutics (TCRT) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is TCRT in an uptrend or downtrend?
As of 2026-10-26, TCRT is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is TCRT's trailing P/E ratio?
TCRT's trailing P/E is -0.90, with a market cap of 0.00B. See the earnings research page for full valuation detail.
When does TCRT next report earnings?
TCRT is next scheduled to report earnings on 2026-08-18.